Royal Bank Of Canada Abb Vie Inc. Call Options Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $6.25 Million - $7.04 Million	45,400 New	45,400 $7.04 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $60.9 Million - $69.9 Million	454,000 New	454,000 $60.9 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $4.04 Million - $4.59 Million	-38,000 Reduced 76.0%	12,000 $1.29 Million
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $5.26 Million - $5.86 Million	50,000 New	50,000 $5.63 Million

3,849

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $312B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.